Having trouble accessing articles? Reset your cache.

Sarepta sinks after FDA rejects DMD therapy

Sarepta dropped $15.61 (13%) to $104.70 in after hours trading Monday, losing over $1.1 billion in market cap, after FDA issued a complete response letter for golodirsen, the biotech's second exon skipping therapy for Duchenne muscular dystrophy.

Sarepta Therapeutics Inc. (NASDAQ:SRPT)

Read the full 407 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE